From Investing.com: 2024-05-18 17:16:54

Dyadic International’s Q1 2024 conference call highlighted progress in human health and animal health sectors, with positive Phase 1 trial results for a COVID-19 vaccine candidate and collaborations in the alternative protein sector. Despite a decrease in research revenue, Dyadic secured a $6 million convertible note financing for near-term revenue growth through strategic partnerships.



Read more at Investing.com: Dyadic International Eyes Growth in Health and Proteins By Investing.com